BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81,774,000 | -3.6% | 11,550,000 | -4.2% | 1.28% | +10.8% |
| Q2 2023 | $84,867,200 | -2.3% | 12,055,000 | +15.7% | 1.15% | -10.6% |
| Q1 2023 | $86,902,800 | -16.4% | 10,420,000 | +15.1% | 1.29% | -17.1% |
| Q4 2022 | $103,894,000 | -8.9% | 9,050,000 | 0.0% | 1.55% | -26.3% |
| Q3 2022 | $114,030,000 | +65.8% | 9,050,000 | +39.2% | 2.11% | +55.0% |
| Q2 2022 | $68,770,000 | +125.6% | 6,500,000 | +246.7% | 1.36% | +144.0% |
| Q1 2022 | $30,488,000 | +1722.4% | 1,875,000 | +450.1% | 0.56% | +415.7% |
| Q4 2017 | $1,673,000 | -82.0% | 340,821 | -80.8% | 0.11% | -85.1% |
| Q3 2017 | $9,319,000 | -14.2% | 1,778,525 | -9.0% | 0.72% | -47.3% |
| Q2 2017 | $10,862,000 | -19.3% | 1,953,525 | +21.9% | 1.37% | -20.2% |
| Q1 2017 | $13,465,000 | +30.4% | 1,603,001 | -1.7% | 1.72% | -17.5% |
| Q4 2016 | $10,327,000 | +69.8% | 1,631,502 | +18.3% | 2.09% | +95.5% |
| Q3 2016 | $6,083,000 | – | 1,379,402 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
| Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
| DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
| Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
| Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
| Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
| KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
| Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |